長期投資家のためのIR情報
バリュートレンド

【4592】サンバイオ
再生細胞薬を開発。

業績予想修正履歴

決算期 日付 予・実 売上高
(百万円)
対前回 修正率 修正率 営業利益
(百万円)
対前回 修正率 修正率 経常利益
(百万円)
対前回 修正率 修正率 当期利益
(百万円)
対前回 修正率 修正率
2025.01 2024/03/18 当初予 - - - - -3,339 - - - -3,359 - - - -3,359 - - -
2024.01 2024/03/18 0 - - - -4,539 +2.2% +2.2% -2,824 +38.6% +38.6% -2,644 +42.5% +42.5%
2024.01 2023/12/14 Q3予 - - - - -4,642 0.0% 0.0% -4,597 0.0% 0.0% -4,598 0.0% 0.0%
2024.01 2023/09/14 Q2予 - - - - -4,642 0.0% 0.0% -4,597 0.0% 0.0% -4,598 0.0% 0.0%
2024.01 2023/06/14 Q1予 - - - - -4,642 0.0% 0.0% -4,597 0.0% 0.0% -4,598 0.0% 0.0%
2024.01 2023/03/16 当初予 - - - - -4,642 - - - -4,597 - - - -4,598 - - -
2023.01 2023/03/16 0 - - - -7,899 +2.9% -34.8% -4,698 -9.3% +21.6% -5,559 +2.2% +7.3%
2023.01 2022/12/15 Q3予 - - - - -8,131 0.0% -38.8% -4,298 0.0% +28.3% -5,684 0.0% +5.2%
2023.01 2022/09/14 Q2予 - - - - -8,131 -38.8% -38.8% -4,298 +28.3% +28.3% -5,684 +5.2% +5.2%
2023.01 2022/06/14 修正予 - - - - -5,858 - - - -5,991 - - - -5,997 - - -
2022.01 2022/03/11 修正予 - - - - -5,858 -1.2% -1.2% -5,991 -2.0% -2.0% -5,997 -2.0% -2.0%
2022.01 2021/12/15 Q3予 - - - - -5,786 0.0% 0.0% -5,876 0.0% 0.0% -5,877 0.0% 0.0%
2022.01 2021/09/14 Q2予 - - - - -5,786 0.0% 0.0% -5,876 0.0% 0.0% -5,877 0.0% 0.0%
2022.01 2021/06/14 Q1予 - - - - -5,786 0.0% 0.0% -5,876 0.0% 0.0% -5,877 0.0% 0.0%
2022.01 2021/03/17 当初予 - - - - -5,786 - - - -5,876 - - - -5,877 - - -
2021.01 2021/03/17 0 - - -5,801 -0.7% -6.4% -6,530 -0.6% -17.8% -3,385 -0.7% +38.9%
2021.01 2021/02/25 修正予 0 - - - -5,761 -5.6% -5.6% -6,490 -17.1% -17.1% -3,363 +39.3% +39.3%
2021.01 2020/12/15 Q3予 - - - - -5,453 0.0% 0.0% -5,543 0.0% 0.0% -5,544 0.0% 0.0%
2021.01 2020/09/14 Q2予 - - - - -5,453 0.0% 0.0% -5,543 0.0% 0.0% -5,544 0.0% 0.0%
2021.01 2020/06/12 Q1予 - - - - -5,453 0.0% 0.0% -5,543 0.0% 0.0% -5,544 0.0% 0.0%
2021.01 2020/03/16 当初予 - - - - -5,453 - - - -5,543 - - - -5,544 - - -
2020.01 2020/03/16 447 0.0% -37.3% -5,486 -7.8% +6.8% -5,146 -11.5% +4.5% -5,157 -11.6% +4.4%
2020.01 2019/12/13 修正予 447 -37.3% -37.3% -5,088 +13.6% +13.6% -4,617 +14.3% +14.3% -4,619 +14.4% +14.4%
2020.01 2019/09/13 Q2予 713 0.0% 0.0% -5,887 0.0% 0.0% -5,390 0.0% 0.0% -5,395 0.0% 0.0%
2020.01 2019/06/14 Q1予 713 0.0% 0.0% -5,887 0.0% 0.0% -5,390 0.0% 0.0% -5,395 0.0% 0.0%
2020.01 2019/03/15 当初予 713 - - - -5,887 - - - -5,390 - - - -5,395 - - -
2019.01 2019/03/15 741 -0.1% -27.7% -3,733 +3.8% -5.5% -2,919 +1.8% -15.4% -2,920 +1.9% -13.9%
2019.01 2019/01/28 修正予 742 -27.6% -27.6% -3,881 -9.6% -9.6% -2,972 -17.5% -17.5% -2,978 -16.1% -16.1%
2019.01 2018/12/14 Q3予 1,025 0.0% 0.0% -3,540 0.0% 0.0% -2,529 0.0% 0.0% -2,564 0.0% 0.0%
2019.01 2018/09/13 Q2予 1,025 0.0% 0.0% -3,540 0.0% 0.0% -2,529 0.0% 0.0% -2,564 0.0% 0.0%
2019.01 2018/06/13 Q1予 1,025 0.0% 0.0% -3,540 0.0% 0.0% -2,529 0.0% 0.0% -2,564 0.0% 0.0%
2019.01 2018/03/13 当初予 1,025 - - - -3,540 - - - -2,529 - - - -2,564 - - -
2018.01 2018/03/13 490 -26.0% -26.0% -4,378 -11.0% -11.0% -3,947 +0.3% +0.3% -3,940 +1.1% +1.1%
2018.01 2017/12/13 Q3予 662 0.0% 0.0% -3,945 0.0% 0.0% -3,957 0.0% 0.0% -3,982 0.0% 0.0%
2018.01 2017/09/12 Q2予 662 0.0% 0.0% -3,945 0.0% 0.0% -3,957 0.0% 0.0% -3,982 0.0% 0.0%
2018.01 2017/06/14 Q1予 662 0.0% 0.0% -3,945 0.0% 0.0% -3,957 0.0% 0.0% -3,982 0.0% 0.0%
2018.01 2017/03/17 当初予 662 - - - -3,945 - - - -3,957 - - - -3,982 - - -
2017.01 2017/03/17 949 +0.2% +7.1% -1,932 -7.1% +49.3% -2,166 +5.9% +43.4% -1,835 +14.1% +49.6%
2017.01 2016/12/14 修正予 947 +6.9% +6.9% -1,804 +52.7% +52.7% -2,301 +39.9% +39.9% -2,136 +41.3% +41.3%
2017.01 2016/06/14 Q1予 886 0.0% 0.0% -3,814 0.0% 0.0% -3,830 0.0% 0.0% -3,641 0.0% 0.0%
2017.01 2016/03/16 当初予 886 - - - -3,814 - - - -3,830 - - - -3,641 - - -
2016.01 2016/03/16 1,174 0.0% -43.4% -1,125 0.0% -3.1% -1,172 0.0% -5.7% -988 0.0% -7.4%
2016.01 2016/02/15 修正予 1,174 -36.0% -43.4% -1,125 -31.6% -3.1% -1,172 -39.9% -5.7% -988 -32.8% -7.4%
2016.01 2015/12/14 Q3予 1,835 0.0% -11.5% -855 0.0% +21.6% -838 0.0% +24.4% -744 0.0% +19.1%
2016.01 2015/09/14 Q2予 1,835 -11.5% -11.5% -855 +21.6% +21.6% -838 +24.4% +24.4% -744 +19.1% +19.1%
2016.01 2015/06/12 当初予 2,074 - - - -1,091 - - - -1,109 - - - -920 - - -
ページトップへ戻る